术后同步放化疗原发性胶质母细胞瘤患者预后影响因素分析  

Influencing factors of prognosis of primary glioblastoma patients undergoing postoperative concurrent ra-diochemotherapy

作　　者：耿亚东 孙德超 孔晨旭 丁炳谦 魏新亭 李振江 GENG Yadong;SUN Dechao;KONG Chenxu;DING Bingqian;WEI Xinting;LI Zhenjiang(Department of Neurosurgery,Huaihe Hospital Affliated to He′nan University,Kaifeng 475000,China)

机构地区：[1]河南大学淮河医院神经外科,河南开封475000

出　　处：《实用医学杂志》2021年第18期2322-2325,共4页The Journal of Practical Medicine

基　　金：河南省医学科技攻关计划(联合共建)项目(编号:LHGJ20190537)。

摘　　要：目的本研究拟通过回顾性研究探讨IDH1、MGMT、p53在术后同步放化疗原发性胶质母细胞瘤(primary glioblastoma,pGBM)中的表达并对其预后进行分析以期指导胶质母细胞瘤患者的个体化、精准化治疗。方法通过电子病历系统获取2014年1月至2018年6月我院及郑大一附院收治的107例术后同步放化疗pGBM患者的临床资料及IDH1基因、MGMT启动子甲基化、p53蛋白表达情况。使用SPSS 21.0统计学软件进行统计学分析。结果术后同步放化疗pGBM患者IDH1突变、mMGMT和p53蛋白阳性表达率分别为9.34%、31.78%、15.89%。年龄≤55岁、非功能区、IDH1突变的术后同步放化疗pGBM患者具有更长的无进展生存期(progression-free survival,PFS)和总生存期(overall survival,OS)(P<0.05)。结论IDH1、肿瘤部位、年龄为术后同步放化疗pGBM患者预后影响因素。IDH1突变预示术后同步放化疗pGBM患者具有更长的PFS和OS,是预测患者预后的重要分子标志物。Objective To explore the expression of IDH1,MGMT,and p53 in primary glioblastoma(pGBM)after postoperative concurrent radiochemotherapy through a retrospective study and analyze its prognosis in order to provide the patients with individualized and precise treatment.Methods The clinical data,IDH1 gene,MGMT promoter methylation,and p53 protein expression of 107 pGBM patients admitted to our hospital and Zhengda First Affiliated Hospital for concurrent radiochemotherapy from January 2014 to June 2018 through the electronic medical record system.Statistical analysis was performed using SPSS 21.0.Results The positive expression rates of IDH1 mutation,mMGMT and p53 protein in the pGBM patients with concurrent radiochemotherapy were 9.34%,31.78%,and 15.89%,respectively.The pGBM patients with age≤55,non-functional area,IDH1 mutation and concurrent radiochemotherapy had longer progression-free survival(PFS)and overall survival(OS)(P<0.05).Conclusion IDH1,tumor location,and age are independent factors affecting the prognosis of pGBM patients with concurrent radiochemotherapy.IDH1 mutation indicates longer PFS and OS in the patients with concurrent radiochemotherapy,and therefore it is an important molecular marker for predicting the prognosis of patients.

关 键 词：原发性胶质母细胞瘤 同步放化疗 IDH1 MGMT 预后 

分 类 号：R651.1[医药卫生—外科学]